ERCC2
WikiDoc Resources for ERCC2 |
Articles |
---|
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on ERCC2 at Clinical Trials.gov Clinical Trials on ERCC2 at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on ERCC2
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Directions to Hospitals Treating ERCC2 Risk calculators and risk factors for ERCC2
|
Healthcare Provider Resources |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
ERCC2, or XPD is a protein involved in transcription-coupled nucleotide excision repair.
The XPD (ERCC2) gene encodes for a 2.3-kb mRNA containing 22 exons and 21 introns. The XPD protein is a 760 amino acids polypeptide with a size of 87kDa. Defects in this gene can result in three different disorders: the cancer-prone syndrome xeroderma pigmentosum complementation group D, trichothiodystrophy, and Cockayne syndrome.[1]
Just like XPB, XPD is also a part of human transcriptional initiation factor TFIIH and has ATP-dependent helicase activity.[2] It belongs to the RAD3/XPD subfamily of helicases.
XPD is essential for the viability of cells. Deletion of XPD in mice is embryonic lethal.
See also
References
- ↑ "Entrez Gene: ERCC2 excision repair cross-complementing rodent repair deficiency, complementation group 2 (xeroderma pigmentosum D)".
- ↑ Lee TI, Young RA (2000). "Transcription of eukaryotic protein-coding genes". Annu. Rev. Genet. 34: 77–137. doi:10.1146/annurev.genet.34.1.77. PMID 11092823.
Further reading
- Broughton BC, Thompson AF, Harcourt SA; et al. (1995). "Molecular and cellular analysis of the DNA repair defect in a patient in xeroderma pigmentosum complementation group D who has the clinical features of xeroderma pigmentosum and Cockayne syndrome". Am. J. Hum. Genet. 56 (1): 167–74. PMID 7825573.
- Jeang KT (1998). "Tat, Tat-associated kinase, and transcription". J. Biomed. Sci. 5 (1): 24–7. PMID 9570510.
- Yankulov K, Bentley D (1998). "Transcriptional control: Tat cofactors and transcriptional elongation". Curr. Biol. 8 (13): R447–9. PMID 9651670.
- Cleaver JE, Thompson LH, Richardson AS, States JC (1999). "A summary of mutations in the UV-sensitive disorders: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy". Hum. Mutat. 14 (1): 9–22. doi:10.1002/(SICI)1098-1004(1999)14:1<9::AID-HUMU2>3.0.CO;2-6. PMID 10447254. Unknown parameter
|doilabel=
ignored (help) - Lehmann AR (2001). "The xeroderma pigmentosum group D (XPD) gene: one gene, two functions, three diseases". Genes Dev. 15 (1): 15–23. PMID 11156600.
- Benhamou S, Sarasin A (2003). "ERCC2/XPD gene polymorphisms and cancer risk". Mutagenesis. 17 (6): 463–9. PMID 12435843.
- Clarkson SG, Wood RD (2006). "Polymorphisms in the human XPD (ERCC2) gene, DNA repair capacity and cancer susceptibility: an appraisal". DNA Repair (Amst.). 4 (10): 1068–74. doi:10.1016/j.dnarep.2005.07.001. PMID 16054878.
External links
- ERCC2+Protein at the US National Library of Medicine Medical Subject Headings (MeSH)